G9D-4
G9D-4 is a G9a PROTAC degrader. G9D-4 induces G9a degradation, reduces H3K9me2 levels, and prevents GLP interference via the CRBN ternary complex, proteasome and ubiquitin-like modification-dependent pathways. G9D-4 exerts antiproliferative activity and induces Apoptosis in pancreatic cancer cells. G9D-4 can be used for research on pancreatic cancer.
(Pink: EHMT2/G9a/KMT1C ligand (HY-15273); Blue: Cereblon ligand (HY-10984); Black: linker).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3097803-96-5
- Fòrmula: C53H75N9O7
- Peso molecular:950.22
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas PROTACs
MoreVer todos los productos específicos de isoformas Histone Methyltransferase
More
Actividad biológica
|
Cereblon |
G9D-4 (0.008-20 μM; 0-24 h) induces G9a degradation in PANC-1 and ASPC-1 cells, with DC50 values of 0.1 μM and 0.2 μM, respectively. It accelerates the degradation of G9a protein in PANC-1 cells without altering GLP protein levels[1].
G9D-4 (0.04-10 μM; 24 h) reduces the level of H3K9me2 in PANC-1 cells[1].
G9D-4 (1 μM; 8 h) induces G9a degradation in PANC-1 cells. This process requires the formation of a G9a-G9D-4-CRBN ternary complex and is dependent on the neddylation-proteasome pathway[1].
G9D-4 (72 h) inhibits the cell growth of a panel of pancreatic cancer cell lines (KP-4, PANC-1, ASPC-1,
HPAF-II, Panc10.05, SW1990, Panc08.13, Panc04.03, Panc05.04, and Panc02.03 cells), with IC50 values ranging from 12 to 32 μM. It also inhibits the growth of 22Rv1 cells, with an IC50 of 9.9 μM[1].
G9D-4 (0.1-12.5 μM; 24 h) induces apoptosis in PANC-1 cells, downregulates G9a and H3K9me2, and upregulates γH2AX and cleaved PARP[1].
G9D-4 (0-15 μM; 72 h) enhances the inhibitory effect of MRTX1133 (HY-134813) on cell proliferation of KRASG12D-mutant pancreatic cancer cell lines (ASPC-1 cells and KP-4 cells), and synergistically induces cell apoptosis[1].
G9D-4 (5-10 μM; 10−14 days) significantly enhances the colony formation inhibitory activity of MRTX1133 in KP-4 cells, and exerts a synergistic inhibitory effect on long-term cell proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PANC-1 cells
-
Concentration:0.008, 0.04, 0.2, 1, 5, 10 μM (dose-response); 1 μM (time-course)
-
Incubation Time:8 h (dose-response); 0, 2, 4, 6, 8, 16, 24 h (time-course)
-
Result:Induced dose-dependent G9a degradation with a DC50 of 0.1 μM. Did not alter GLP protein levels.
Triggered G9a degradation starting after 8 h and continuing through 24 h.
Selectively and dose-dependently reduced H3K9me2 levels.
Induced significant G9a degradation as early as 4 h.
-
Cell Line:PANC-1 cells
-
Concentration:5-12.5 μM (24 h); 10 μM (time-course)
-
Incubation Time:24 h (dose-response); 12, 24, 48, 72 h (time-course)
-
Result:Induced significant apoptosis in a dose-dependent manner at 24 h, with ~70% of cells apoptotic at 12.5 μM.
Caused time-dependent apoptosis at 10 μM, with ~60% of cells apoptotic at 72 h.
-
Cell Line:ASPC-1 cells
-
Concentration:0.008, 0.04, 0.2, 1, 5, 10, 15, 20 μM
-
Incubation Time:8 h
-
Result:Induced dose-dependent G9a degradation with a DC50 of 0.2 μM.
Did not alter GLP protein levels.
-
Cell Line:PANC-1 cells
-
Concentration:0.1, 1, 10 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced G9a and H3K9me2 levels.
Dose-dependently increased γH2AX and cleaved PARP levels, indicating induction of DNA damage and apoptosis.
-
Cell Line:ASPC-1, KP-4, Panc02.03, Panc10.05, HPAFII, Panc08.13 KRASG12D mutant pancreatic cancer cell lines
-
Concentration:30 μM starting concentration, 1.2-fold serial dilutions (ASPC-1); 20 μM starting concentration, 1.2-fold serial dilutions (KP-4); fixed concentrations (co-treated with MRTX1133)
-
Incubation Time:72 h
-
Result:Combined with MRTX1133 showed strong synergistic antiproliferative activity. Had all CI values below 0.8 (ED50, ED75, ED90), with ED90 CI values below 0.4 across all tested cell lines.
-
Cell Line:KP-4, ASPC-1 cells
-
Concentration:5-10 μM (alone); 5-10 μM (co-treated with 1-5 μM MRTX1133, respectively)
-
Incubation Time:10-14 days
-
Result:Alone reduced colony formation. Combined with MRTX1133 almost completely eliminated colony formation, with a significantly greater effect than either single agent.
-
Cell Line:ASPC-1, KP-4 cells
-
Concentration:10 μM (co-treated with 1 μM MRTX1133, ASPC-1); 10 μM (co-treated with 5 μM MRTX1133, KP-4)
-
Incubation Time:24 h
-
Result:Combined with MRTX1133 induced significantly higher levels of apoptosis than either single agent.
Triggered ~75% apoptosis in ASPC-1 cells. Triggered ~30% apoptosis in KP-4 cells.
-
Cell Line:ASPC-1 cells
-
Concentration:10 μM (co-treated with 1 μM MRTX1133)
-
Incubation Time:24 h
-
Result:Combined with MRTX1133 further reduced H3K9me2 levels and significantly increased γH2AX and cleaved PARP levels compared to either single agent.
Chemical Information
-
No. CAS 3097803-96-5
-
Peso molecular 950.22
-
Fòrmula C53H75N9O7
-
SMILES
COC1=CC2=C(C=C1OCCCN3CCCC3)N=C(C4CCCCC4)N=C2NC5CCN(CC5)CCCC(NCCCCCCCCCNC6=C(C7=CC=C6)C(N(C7=O)C8C(NC(CC8)=O)=O)=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)